[go: up one dir, main page]

FR2697250B1 - Dérivés de beta,beta-diméthyl-4-pipéridineéthanol et de 1,2,3,6-tétrahydro-beta,beta-diméthyl-4-pyridineéthanol, leur procédé de préparation et leur utilisation en thérapeutique. - Google Patents

Dérivés de beta,beta-diméthyl-4-pipéridineéthanol et de 1,2,3,6-tétrahydro-beta,beta-diméthyl-4-pyridineéthanol, leur procédé de préparation et leur utilisation en thérapeutique.

Info

Publication number
FR2697250B1
FR2697250B1 FR9212866A FR9212866A FR2697250B1 FR 2697250 B1 FR2697250 B1 FR 2697250B1 FR 9212866 A FR9212866 A FR 9212866A FR 9212866 A FR9212866 A FR 9212866A FR 2697250 B1 FR2697250 B1 FR 2697250B1
Authority
FR
France
Prior art keywords
beta
dimethyl
pyridineethanol
piperidineethanol
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9212866A
Other languages
English (en)
Other versions
FR2697250A1 (fr
Inventor
Jean Binet
Soth Samreth
Daniel De Fornel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fournier Industrie et Sante SAS
Original Assignee
Fournier Industrie et Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Industrie et Sante SAS filed Critical Fournier Industrie et Sante SAS
Priority to FR9212866A priority Critical patent/FR2697250B1/fr
Publication of FR2697250A1 publication Critical patent/FR2697250A1/fr
Application granted granted Critical
Publication of FR2697250B1 publication Critical patent/FR2697250B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR9212866A 1992-10-28 1992-10-28 Dérivés de beta,beta-diméthyl-4-pipéridineéthanol et de 1,2,3,6-tétrahydro-beta,beta-diméthyl-4-pyridineéthanol, leur procédé de préparation et leur utilisation en thérapeutique. Expired - Fee Related FR2697250B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9212866A FR2697250B1 (fr) 1992-10-28 1992-10-28 Dérivés de beta,beta-diméthyl-4-pipéridineéthanol et de 1,2,3,6-tétrahydro-beta,beta-diméthyl-4-pyridineéthanol, leur procédé de préparation et leur utilisation en thérapeutique.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9212866A FR2697250B1 (fr) 1992-10-28 1992-10-28 Dérivés de beta,beta-diméthyl-4-pipéridineéthanol et de 1,2,3,6-tétrahydro-beta,beta-diméthyl-4-pyridineéthanol, leur procédé de préparation et leur utilisation en thérapeutique.

Publications (2)

Publication Number Publication Date
FR2697250A1 FR2697250A1 (fr) 1994-04-29
FR2697250B1 true FR2697250B1 (fr) 1995-01-20

Family

ID=9434931

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9212866A Expired - Fee Related FR2697250B1 (fr) 1992-10-28 1992-10-28 Dérivés de beta,beta-diméthyl-4-pipéridineéthanol et de 1,2,3,6-tétrahydro-beta,beta-diméthyl-4-pyridineéthanol, leur procédé de préparation et leur utilisation en thérapeutique.

Country Status (1)

Country Link
FR (1) FR2697250B1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
JP2013528172A (ja) 2010-05-21 2013-07-08 ファイザー・インク ２−フェニルベンゾイルアミド
CA2828343A1 (fr) 2011-03-04 2012-09-13 The Scripps Research Institute Peptides de type edn3 et utilisations associees
CA2909442A1 (fr) 2013-04-17 2014-10-23 Pfizer Inc. Derives de n-piperidin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
EP4470609A3 (fr) 2019-01-18 2025-03-12 Astrazeneca AB Inhibiteurs de pcsk9 et leurs procédés d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2025490C (fr) * 1989-09-22 2003-09-16 James R. Mccarthy Alkyl piperidines subtituees et leur utilisation comme inhibiteurs de la synthese du cholesterol
AU638852B2 (en) * 1990-07-24 1993-07-08 Merrell Dow Pharmaceuticals Inc. Novel substituted piperidines and their use as inhibitors of cholesterol synthesis
ZA915659B (en) * 1990-07-25 1992-05-27 Merrell Dow Pharma Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis

Also Published As

Publication number Publication date
FR2697250A1 (fr) 1994-04-29

Similar Documents

Publication Publication Date Title
DZ418A1 (fr) Dérivés de céphalosporine, leur procédé de préparation et leur application thérapeutique.
FR2696176B1 (fr) Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
FR2629715B1 (fr) Derives de l'adenosine, leur procede de preparation et leur utilisation en therapeutique
FR2709754B1 (fr) Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
EP0278453A3 (en) 2,4- and 2,5-pyridine-dicarboxylic-acid derivatives, process for their preparation, their use and medicines based on these compounds
OA07699A (fr) Dérivés de la furo-(3,4-c)-pyridine leur préparation et compositions thérapeutiques contenant ces dérivés.
FR2696744B1 (fr) Dérivés de 2-pyrrolidone, leur procédé de préparation et leurs applications en thérapeutique.
OA06951A (fr) Dérivés de la thiéno-pyridinone, leur procédé de préparation et leur application thérapeutique.
FR2702660B1 (fr) Compositions thérapeutiques stabilisées et leur procédé de préparation.
AR243180A1 (es) Procedimiento para la obtencion de 3,4-dihidro-2h-benzopiranos sustituidos.
FR2697250B1 (fr) Dérivés de beta,beta-diméthyl-4-pipéridineéthanol et de 1,2,3,6-tétrahydro-beta,beta-diméthyl-4-pyridineéthanol, leur procédé de préparation et leur utilisation en thérapeutique.
EP0278452A3 (en) 2,4- and 2,5-pyridine-dicarboxylic-acid derivatives, process for their preparation, their use and medicines based on these compounds
EP0659779A3 (fr) Microsphères et procédé de leur préparation.
OA09840A (fr) dérivés de pipéridine, leur préparation et leur application en thérapeutique
FR2691464B1 (fr) Nouveaux dérivés de la 1-oxa 6-azacyclopentadécane 13,15-dione, leur procédé de préparation et leur application comme médicaments.
DZ687A1 (fr) Dérivés de la chlori-4-furo-(3,4-c)-pyridine et leur procédé de préparation.
FR2699920B1 (fr) Dérivés d'imidazo [2,1-b] benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique.
FR2702211B1 (fr) Nouveaux dérivés de la phénoxy-2 éthylamine, leur préparation et leur application en thérapeutique.
FR2700337B1 (fr) Dérivés d'imidazopyridine-2-one, leur procédé de préparation et leur utilisation en thérapeutique.
FR2693197B1 (fr) Nouveaux dérivés de quinoléine, leur procédé de préparation et leur application thérapeutique.
OA09302A (fr) Nouveaux dérivés d'oxazolo pyridines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
FR2699919B1 (fr) Dérivés d'imidazole, leur procédé de préparation et leur application en thérapeutique.
OA07133A (fr) Dérivés de benzoyl-phényl-pipéridine, procédé de préparation et application en thérapeutique.
FR2697253B1 (fr) Dérivés de 2-aminopyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique.
FR2700546B1 (fr) Dérivés d'imidazo[2,1-b]benzoxazole-3-acétamide, leur préparation et leur application en thérapeutique.

Legal Events

Date Code Title Description
ST Notification of lapse